Yaqin Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yaqin Shi has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Xiaoxiang Guan
The First Affiliated Hospital of Nanjing Medical University
4 shared publications Fangyan Gao
Department of Oncology The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China
2 shared publications- Juan Jin
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
2 shared publications - Kai Chen
Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China
2 shared publications Linlin Lu
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China
2 shared publications- Xinyu Zhu
School of Public Health, Suzhou Medical College of Soochow University, Suzhou 215123, China
2 shared publications
Latest Publications
- Open Access
- 29 September 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (10) , e70484
Targeting c‐Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple‐negative breast cancer
Background: Triple‐negative breast cancer (TNBC), which lacks hormone receptors and HER2 expression, presents substantial therapeutic challenges in breast cancer treatment. The efficacy of immunotherapy frequently suffers from the immunosuppressive nature of tumour microenvironment (TME). Hence, discovering effective targets to hinder TNBC progression and bolster immunotherapy's effectiveness is paramount. Previous research from our team indicated notable upregulation of c‐Myc in TNBC, and suppressing c‐Myc enhances the efficacy of PD‐L1 blockade in murine models; nevertheless, the precise mechanisms underlying this phenomenon remain elusive. Methods: We analysed c‐Myc expression and implemented a systematic drug library screening strategy alongside c‐Myc knockdown to pinpoint potential synergistic agents in TNBC cells. To decipher the regulatory mechanisms of this synergy on cellular malignancy, we conducted cell cycle analysis, cell interaction assays, and RNA‐sequencing. Additionally, we established orthotopic and lung metastasis murine models assess how combination therapy influences PD‐L1 blockade efficacy. Results: Elevated c‐Myc was observed in TNBC and the Ras inhibitor Salirasib was identified as a potent synergistic agent from cell cycle drug library in c‐Myc‐overexpressing TNBC. The application of Salirasib combined with c‐Myc knockdown markedly suppressed tumour cell aggressiveness and induced apoptosis in vitro. Mechanistically, RNA sequencing revealed that the combination therapy blocked MCM2‐mediated DNA replication in TNBC cells, causing G1/S phase arrest and enhancing tumour suppression. In vivo, the combination significantly improved PD‐L1 blockade efficacy, leading to reduction of tumour volume, inhibition of lung metastases, and remodelling of the immune microenvironment in murine TNBC models. Conclusions: In summary, our investigation identifies a molecular vulnerability in c‐Myc‐driven TNBC, where Ras inhibition reinforces c‐Myc‐targeted therapy and potentiates immune checkpoint blockade, presenting a promising strategy to improve immunotherapy efficacy in TNBC.
- 29 September 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (10) , e70484
Open AccessTargeting c‐Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple‐negative breast cancer
Background: Triple‐negative breast cancer (TNBC), which lacks hormone receptors and HER2 expression, presents substantial therapeutic challenges in breast cancer treatment. The efficacy of immunotherapy frequently suffers from the immunosuppressive nature of tumour microenvironment (TME). Hence, discovering effective targets to hinder TNBC progression and bolster immunotherapy's effectiveness is paramount. Previous research from our team indicated notable upregulation of c‐Myc in TNBC, and suppressing c‐Myc enhances the efficacy of PD‐L1 blockade in murine models; nevertheless, the precise mechanisms underlying this phenomenon remain elusive. Methods: We analysed c‐Myc expression and implemented a systematic drug library screening strategy alongside c‐Myc knockdown to pinpoint potential synergistic agents in TNBC cells. To decipher the regulatory mechanisms of this synergy on cellular malignancy, we conducted cell cycle analysis, cell interaction assays, and RNA‐sequencing. Additionally, we established orthotopic and lung metastasis murine models assess how combination therapy influences PD‐L1 blockade efficacy. Results: Elevated c‐Myc was observed in TNBC and the Ras inhibitor Salirasib was identified as a potent synergistic agent from cell cycle drug library in c‐Myc‐overexpressing TNBC. The application of Salirasib combined with c‐Myc knockdown markedly suppressed tumour cell aggressiveness and induced apoptosis in vitro. Mechanistically, RNA sequencing revealed that the combination therapy blocked MCM2‐mediated DNA replication in TNBC cells, causing G1/S phase arrest and enhancing tumour suppression. In vivo, the combination significantly improved PD‐L1 blockade efficacy, leading to reduction of tumour volume, inhibition of lung metastases, and remodelling of the immune microenvironment in murine TNBC models. Conclusions: In summary, our investigation identifies a molecular vulnerability in c‐Myc‐driven TNBC, where Ras inhibition reinforces c‐Myc‐targeted therapy and potentiates immune checkpoint blockade, presenting a promising strategy to improve immunotherapy efficacy in TNBC.
- Open Access
- 26 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (10) , 2366
Comprehensive Analysis of JCHAIN as a Potential Prognostic Factor for Breast Cancer and an Indicator for Tumor Microenvironment
Background: Breast cancer remains a predominant malignancy among females globally, and the tumor microenvironment (TME) exerts a pivotal role in its progression. Despite notable advancements in diagnostic and therapeutic modalities, resistance to conventional therapies persists as a critical hurdle, underscoring the necessity of exploring TME-related prognostic biomarkers. Methods: To elucidate the role of the TME in breast cancer progression and identify potential prognostic biomarkers, we analyzed RNA-seq data from 1081 breast cancer cases and 99 normal controls to assess tumor-infiltrating immune cells (TICs) and stromal components. Differential gene expression analysis identified genes correlated with ImmuneScore and StromalScore. A protein–protein interaction (PPI) network was constructed, followed by univariate Cox regression to pinpoint survival-associated genes. JCHAIN, significantly linked to survival outcomes, was selected for further investigation. Gene Set Enrichment Analysis (GSEA) and TIC correlation analyses were performed to explore its associations with immune pathways. Additionally, immunohistochemistry (IHC) and multiplexed immunofluorescence (mIF) were performed on 61 clinical samples. Results: High ImmuneScore was associated with improved survival. Joining chain of multimeric IgA and IgM (JCHAIN) expression was notably reduced in tumor tissues, with low expression correlating with poorer prognosis. GSEA highlighted immune-related pathways enriched in high JCHAIN expression groups. TIC analysis revealed positive correlations with CD8+ T cells and M1 macrophages. IHC and mIF validations further confirmed decreased JCHAIN protein expression in tumor tissues, and higher JCHAIN expression was associated with increased M1 macrophage density. Conclusions: JCHAIN serves as a promising prognostic biomarker in breast cancer, reflecting immune activity within the TME, providing valuable insights into immune-stromal interactions and the therapeutic potential of JCHAIN.
- 26 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (10) , 2366
Open AccessComprehensive Analysis of JCHAIN as a Potential Prognostic Factor for Breast Cancer and an Indicator for Tumor Microenvironment
Background: Breast cancer remains a predominant malignancy among females globally, and the tumor microenvironment (TME) exerts a pivotal role in its progression. Despite notable advancements in diagnostic and therapeutic modalities, resistance to conventional therapies persists as a critical hurdle, underscoring the necessity of exploring TME-related prognostic biomarkers. Methods: To elucidate the role of the TME in breast cancer progression and identify potential prognostic biomarkers, we analyzed RNA-seq data from 1081 breast cancer cases and 99 normal controls to assess tumor-infiltrating immune cells (TICs) and stromal components. Differential gene expression analysis identified genes correlated with ImmuneScore and StromalScore. A protein–protein interaction (PPI) network was constructed, followed by univariate Cox regression to pinpoint survival-associated genes. JCHAIN, significantly linked to survival outcomes, was selected for further investigation. Gene Set Enrichment Analysis (GSEA) and TIC correlation analyses were performed to explore its associations with immune pathways. Additionally, immunohistochemistry (IHC) and multiplexed immunofluorescence (mIF) were performed on 61 clinical samples. Results: High ImmuneScore was associated with improved survival. Joining chain of multimeric IgA and IgM (JCHAIN) expression was notably reduced in tumor tissues, with low expression correlating with poorer prognosis. GSEA highlighted immune-related pathways enriched in high JCHAIN expression groups. TIC analysis revealed positive correlations with CD8+ T cells and M1 macrophages. IHC and mIF validations further confirmed decreased JCHAIN protein expression in tumor tissues, and higher JCHAIN expression was associated with increased M1 macrophage density. Conclusions: JCHAIN serves as a promising prognostic biomarker in breast cancer, reflecting immune activity within the TME, providing valuable insights into immune-stromal interactions and the therapeutic potential of JCHAIN.
- 17 September 2025
- Published by Springer Nature in Science China Life Sciences
- Vol. 69 (1) , 85-100
AR/ERK co-targeting triggers ferroptosis via FOXC2 in triple-negative breast cancer
Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, notably lacks effective treatment strategies. Although androgen receptor (AR) has emerged as a potential therapeutic target for TNBC, monotherapy with AR inhibitors has proven to be of restricted efficacy. Aiming to develop superior therapeutic approaches, a comprehensive drug library screening was conducted. The ERK inhibitor GDC-0994 exhibited significant synergistic effects with the AR inhibitor bicalutamide. Transcriptome sequencing showed that this combination therapy activates ferroptosis, as evidenced by elevated ROS, increased Fe2+ levels, a reduced GSH/GSSG ratio, and lipid peroxide accumulation (MDA and 4-HNE). FOXC2 was identified as a key mediator of this synergy. Specifically, the combination therapy inhibits FOXC2-driven EMT and induces ferroptosis via the FOXC2-Hippo signaling axis, suppressing tumor proliferation, migration, and invasion. In summary, this study uncovers the value of AR/ERK co-targeting in TNBC, which might potentiate the development of novel targeted therapeutic strategies in TNBC.
- 17 September 2025
- Published by Springer Nature in Science China Life Sciences
- Vol. 69 (1) , 85-100
AR/ERK co-targeting triggers ferroptosis via FOXC2 in triple-negative breast cancer
Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, notably lacks effective treatment strategies. Although androgen receptor (AR) has emerged as a potential therapeutic target for TNBC, monotherapy with AR inhibitors has proven to be of restricted efficacy. Aiming to develop superior therapeutic approaches, a comprehensive drug library screening was conducted. The ERK inhibitor GDC-0994 exhibited significant synergistic effects with the AR inhibitor bicalutamide. Transcriptome sequencing showed that this combination therapy activates ferroptosis, as evidenced by elevated ROS, increased Fe2+ levels, a reduced GSH/GSSG ratio, and lipid peroxide accumulation (MDA and 4-HNE). FOXC2 was identified as a key mediator of this synergy. Specifically, the combination therapy inhibits FOXC2-driven EMT and induces ferroptosis via the FOXC2-Hippo signaling axis, suppressing tumor proliferation, migration, and invasion. In summary, this study uncovers the value of AR/ERK co-targeting in TNBC, which might potentiate the development of novel targeted therapeutic strategies in TNBC.
- Open Access
- 3 January 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status
Despite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alongside the development of HER2-targeted therapies, has significantly improved the prognosis of HER2-amplified breast cancers. However, therapeutic options remain limited for HER2-overexpressing or HER2-negative breast cancers. In response to this gap, antibody-drug conjugates (ADCs) have emerged as a promising approach. ADCs combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy, which allows for the targeted delivery of a cytotoxic payload to cancer cells. ADCs have been used as adjuvant chemotherapeutic treatments and salvage therapies across various breast cancer subtypes, which have greatly improved the prognosis of breast cancer patients. Numerous ongoing clinical trials seek to optimize dosing strategies and identify patient populations that would benefit most from ADCs. This review presents an updated and comprehensive overview of emerging investigational ADCs for treating breast cancer patients with various HER2 subtypes. These ADCs are spearheading a new era in targeted cancer therapy, promising to innovate treatment paradigms for both HER2-positive and HER2-low breast cancers.
- 3 January 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Open AccessRecent advances of antibody-drug conjugates in treating breast cancer with different HER2 status
Despite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alongside the development of HER2-targeted therapies, has significantly improved the prognosis of HER2-amplified breast cancers. However, therapeutic options remain limited for HER2-overexpressing or HER2-negative breast cancers. In response to this gap, antibody-drug conjugates (ADCs) have emerged as a promising approach. ADCs combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy, which allows for the targeted delivery of a cytotoxic payload to cancer cells. ADCs have been used as adjuvant chemotherapeutic treatments and salvage therapies across various breast cancer subtypes, which have greatly improved the prognosis of breast cancer patients. Numerous ongoing clinical trials seek to optimize dosing strategies and identify patient populations that would benefit most from ADCs. This review presents an updated and comprehensive overview of emerging investigational ADCs for treating breast cancer patients with various HER2 subtypes. These ADCs are spearheading a new era in targeted cancer therapy, promising to innovate treatment paradigms for both HER2-positive and HER2-low breast cancers.
- 6 November 2023
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 80 (12) , 1-14
Exploring the therapeutic potential of ADC combination for triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer. Currently, standard treatment options for TNBC are limited to surgery, adjuvant chemotherapy, and radiotherapy. However, these treatment methods are associated with a higher risk of intrinsic or acquired recurrence. Antibody–drug conjugates (ADCs) have emerged as a useful and promising class of cancer therapeutics. ADCs, also known as “biochemical missiles”, use a monoclonal antibody (mAb) to target tumor antigens and deliver a cytotoxic drug payload. Currently, several ADCs clinical studies are underway worldwide, including sacituzumab govitecan (SG), which was recently approved by the FDA for the treatment of TNBC. However, due to the fact that only a small portion of TNBC patients respond to ADC therapy and often develop resistance, growing evidence supports the use of ADCs in combination with other treatment strategies to treat TNBC. In this review, we described the current utilization of ADCs and discussed the prospects of ADC combination therapy for TNBC.
- 6 November 2023
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 80 (12) , 1-14
Exploring the therapeutic potential of ADC combination for triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer. Currently, standard treatment options for TNBC are limited to surgery, adjuvant chemotherapy, and radiotherapy. However, these treatment methods are associated with a higher risk of intrinsic or acquired recurrence. Antibody–drug conjugates (ADCs) have emerged as a useful and promising class of cancer therapeutics. ADCs, also known as “biochemical missiles”, use a monoclonal antibody (mAb) to target tumor antigens and deliver a cytotoxic drug payload. Currently, several ADCs clinical studies are underway worldwide, including sacituzumab govitecan (SG), which was recently approved by the FDA for the treatment of TNBC. However, due to the fact that only a small portion of TNBC patients respond to ADC therapy and often develop resistance, growing evidence supports the use of ADCs in combination with other treatment strategies to treat TNBC. In this review, we described the current utilization of ADCs and discussed the prospects of ADC combination therapy for TNBC.
- Open Access
- 19 April 2023
- Published by Springer Nature in Research Square
Exploring the therapeutic potential of ADC combination for triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer. Standard treatment options for TNBC mainly involve surgery, radiation treatment, and chemotherapy. Such treatment, however, are linked to a high risk of relapses both locally and systemically. Antibody-drug conjugates (ADCs) have recently arisen as a useful and promising option for cancer treatment. ADCs, referred to as "biological missiles", are composed of monoclonal antibodies (mAbs) that target the tumor antigens and deliver anticancer drugs as a payload. As of right now, several ADCs are undergoing clinical research around the world, including sacituzumab govitecan (SG) approved recently by the FDA for the treatment of TNBC. Due to the fact that only a small proportion of patients with TNBC respond to ADC therapy, and that drug resistance often occurs, growing evidence supports combination strategies using ADCs to treat TNBC. Herein, we described the current utilization of ADCs and discussed the prospect of combining ADCs with other therapies for treating TNBC.
- 19 April 2023
- Published by Springer Nature in Research Square
Open AccessExploring the therapeutic potential of ADC combination for triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer. Standard treatment options for TNBC mainly involve surgery, radiation treatment, and chemotherapy. Such treatment, however, are linked to a high risk of relapses both locally and systemically. Antibody-drug conjugates (ADCs) have recently arisen as a useful and promising option for cancer treatment. ADCs, referred to as "biological missiles", are composed of monoclonal antibodies (mAbs) that target the tumor antigens and deliver anticancer drugs as a payload. As of right now, several ADCs are undergoing clinical research around the world, including sacituzumab govitecan (SG) approved recently by the FDA for the treatment of TNBC. Due to the fact that only a small proportion of patients with TNBC respond to ADC therapy, and that drug resistance often occurs, growing evidence supports combination strategies using ADCs to treat TNBC. Herein, we described the current utilization of ADCs and discussed the prospect of combining ADCs with other therapies for treating TNBC.
- Open Access
- 14 July 2018
- Published by Springer Nature in Molecular Cancer
- Vol. 17 (1) , 1-11
Therapeutic landscape in mutational triple negative breast cancer
Triple negative breast cancer (TNBC) is a heterogeneous disease with aggressive behavior and poor prognosis. Genomic sequencing has detected a distinctive mutational portrait of both the germline and somatic alterations in TNBC, which is staggeringly different from other breast cancer subtypes. The clinical utility of sequencing germline BRCA1/2 genes has been well established in TNBC. However, for other predisposition genes, studies concerning the risk and penetrance to TNBC are relatively scarce. Very few recurrent mutations, including TP53 and PI3KCA mutations, together with a long tail of individually rare mutations occur in TNBC. These combined effects of genomic alterations drive TNBC progression. Given the complexity and heterogeneity of TNBC, clinical interpretation of the genomic alterations in TNBC may pave a new way for the treatment of TNBC. In this review, we summarized the germline and somatic mutation profiles of TNBC and discussed the current and upcoming therapeutic strategies targeting the mutant proteins or pathways to enable tailored-therapeutics.
- 14 July 2018
- Published by Springer Nature in Molecular Cancer
- Vol. 17 (1) , 1-11
Open AccessTherapeutic landscape in mutational triple negative breast cancer
Triple negative breast cancer (TNBC) is a heterogeneous disease with aggressive behavior and poor prognosis. Genomic sequencing has detected a distinctive mutational portrait of both the germline and somatic alterations in TNBC, which is staggeringly different from other breast cancer subtypes. The clinical utility of sequencing germline BRCA1/2 genes has been well established in TNBC. However, for other predisposition genes, studies concerning the risk and penetrance to TNBC are relatively scarce. Very few recurrent mutations, including TP53 and PI3KCA mutations, together with a long tail of individually rare mutations occur in TNBC. These combined effects of genomic alterations drive TNBC progression. Given the complexity and heterogeneity of TNBC, clinical interpretation of the genomic alterations in TNBC may pave a new way for the treatment of TNBC. In this review, we summarized the germline and somatic mutation profiles of TNBC and discussed the current and upcoming therapeutic strategies targeting the mutant proteins or pathways to enable tailored-therapeutics.